‘Leclaza to get coverage for 1st- and 2nd-line treatment of lung cancer’

Yuhan Corp. said Thursday that Leclaza (lazertinib mesylate monohydrate), a treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), will receive insurance benefits for the first-line treatment starting Jan. 1, 2024.The coverage expansion will allow